+44 7474964491
[email protected]
Contact Us

Blogs

Stay informed with the latest trends, updates, and expert insights in quality assurance, regulatory affairs, and compliance. Our blogs are designed to keep you ahead in the ever-evolving world of healthcare and pharmaceuticals.

Subscribe Now
CE Mark vs National Device Approvals: How Global Medical Device Manufacturers Should Plan Their Compliance Strategy in 2026
28 May
Pharmacovigilance Services

CE Mark vs National Device Approvals: How Global Medical Device Manufacturers Should Plan Their Compliance Strategy in 2026

EMA, FDA and MHRA GMP Annex Revisions 2026- 2028: What Every Pharma QA Team Must Prepare For
26 May
Pharma Audits

EMA, FDA and MHRA GMP Annex Revisions 2026- 2028: What Every Pharma QA Team Must Prepare For

GMP Mock Inspection for Pharmaceutical Manufacturers: What Global Regulators Check That Internal Teams Miss
21 May
Pharma Audits

GMP Mock Inspection for Pharmaceutical Manufacturers: What Global Regulators Check That Internal Teams Miss

How to Respond to a Regulatory Deficiency Letter: A Step-by-Step CAPA Guide for Pharmaceutical Sites
19 May
GVP Audits Pharma Audits

How to Respond to a Regulatory Deficiency Letter: A Step-by-Step CAPA Guide for Pharmaceutical Sites

EU QPPV Services: Cost Comparison In-House vs Outsourced QPPV for MAHs in 2026
14 May
Pharmacovigilance Services

EU QPPV Services: Cost Comparison In-House vs Outsourced QPPV for MAHs in 2026

End-to-End GxP Quality and Pharmacovigilance Services: Integrated vs Fragmented PV
12 May
Pharmacovigilance Services

End-to-End GxP Quality and Pharmacovigilance Services: Integrated vs Fragmented PV

Drug Safety Consulting for Social Media ADR Reporting: NLP and Data Mining Strategies
07 May
Pharmacovigilance Services

Drug Safety Consulting for Social Media ADR Reporting: NLP and Data Mining Strategies

GxP Quality Services: FDA’s 112 Warning Letters and System Misalignment Findings
05 May
Risk-Based Audits

GxP Quality Services: FDA’s 112 Warning Letters and System Misalignment Findings

Pharmacovigilance Audit Services: Verifying Social Media Listening Programs for Regulatory Compliance
30 Apr
Pharmacovigilance Services

Pharmacovigilance Audit Services: Verifying Social Media Listening Programs for Regulatory Compliance

DARWIN EU Real-World Evidence: How Drug Safety Consulting Services Use 250 Million Patient Records
28 Apr
Pharma Audits

DARWIN EU Real-World Evidence: How Drug Safety Consulting Services Use 250 Million Patient Records

Before Your QA Meeting: 10 Quality Signals Every Leader Should Track
23 Apr
Pharma Audits Risk-Based Audits

Before Your QA Meeting: 10 Quality Signals Every Leader Should Track

Evidence Collection Flaws That Trigger Escalated Observations in Hybrid Audits
21 Apr
GVP Audits Pharma Audits

Evidence Collection Flaws That Trigger Escalated Observations in Hybrid Audits

Visual Inspection 4.0: Machines That Never Miss a Defect (And Regulators Love It)
16 Apr
Pharma Audits

Visual Inspection 4.0: Machines That Never Miss a Defect (And Regulators Love It)

How to Survive a Hybrid GMP Inspection Without a Single Observation
14 Apr
Pharmacovigilance Services Risk-Based Audits

How to Survive a Hybrid GMP Inspection Without a Single Observation

RMP 2.0: Digital Risk Management Plans Every Clinical Team Should Be Using
09 Apr
Risk-Based Audits

RMP 2.0: Digital Risk Management Plans Every Clinical Team Should Be Using

Biosimilars Under the Microscope: Post-Marketing Safety Shifts You Can’t Ignore
07 Apr
Pharmacovigilance Services

Biosimilars Under the Microscope: Post-Marketing Safety Shifts You Can’t Ignore

E2B(R3) Deadline April 2026: Is Your ICSR Submission Process FDA-Ready?
02 Apr
Pharmacovigilance Services

E2B(R3) Deadline April 2026: Is Your ICSR Submission Process FDA-Ready?

Annex 15 Revision: Key Impacts on Qualification and Validation for GDP Operators
31 Mar
Pharma Audits

Annex 15 Revision: Key Impacts on Qualification and Validation for GDP Operators

Navigating Dual MHRA/EMA Pharmacovigilance Obligations Post-Windsor Framework
26 Mar
Pharmacovigilance Services

Navigating Dual MHRA/EMA Pharmacovigilance Obligations Post-Windsor Framework

EU GMP Annex 22 (Artificial Intelligence): What GMP-Regulated Manufacturers Must Do Before the Effective Date
24 Mar
Pharmacovigilance Services

EU GMP Annex 22 (Artificial Intelligence): What GMP-Regulated Manufacturers Must Do Before the Effective Date

EU Pharma Package 2026: What It Means for GMP/GDP Operators Now
19 Mar
Pharma Audits

EU Pharma Package 2026: What It Means for GMP/GDP Operators Now

EudraVigilance Data Masking in ICSRs: Breaking Down the New GVP Module VI Addendum II
17 Mar
Pharmacovigilance Services

EudraVigilance Data Masking in ICSRs: Breaking Down the New GVP Module VI Addendum II

AI-Powered Signal Detection in 2026: Regulation, Use & Inspector Expectations
12 Mar
Risk-Based Audits

AI-Powered Signal Detection in 2026: Regulation, Use & Inspector Expectations

Third‑Party PV Subcontractors in the Crosshairs: How to Audit‑Proof Your Vendor Agreements
10 Mar
Pharma Audits

Third‑Party PV Subcontractors in the Crosshairs: How to Audit‑Proof Your Vendor Agreements

GVP Module IX Update in Q2 2026: What’s Changing and How to Prepare Now
05 Mar
GVP Audits

GVP Module IX Update in Q2 2026: What’s Changing and How to Prepare Now

Signal Management Overhaul: How to Adapt Your SOPs After the Deletion of Article 21(2)
03 Mar
Pharmacovigilance Services

Signal Management Overhaul: How to Adapt Your SOPs After the Deletion of Article 21(2)

ESMP Compliance in 2026: EMA Pharmacovigilance & Shortage Reporting Essentials
26 Feb
Pharmacovigilance Services

ESMP Compliance in 2026: EMA Pharmacovigilance & Shortage Reporting Essentials

Unannounced FDA GMP Inspections: Readiness Guide for Foreign Facilities
24 Feb
GVP Audits

Unannounced FDA GMP Inspections: Readiness Guide for Foreign Facilities

ICH E6(R3) & CRO Oversight: Risk-Based Vendor Audit Strategies
19 Feb
Risk-Based Audits

ICH E6(R3) & CRO Oversight: Risk-Based Vendor Audit Strategies

EU Pharmacovigilance Regulation 2025/1466: GvP Vendor Audit Essentials Before Feb 2026
17 Feb
Pharmacovigilance Services

EU Pharmacovigilance Regulation 2025/1466: GvP Vendor Audit Essentials Before Feb 2026

Why 87% of FDA Warning Letters Require External GMP Consultants
12 Feb
Pharma Audits

Why 87% of FDA Warning Letters Require External GMP Consultants

GDP Compliance Support for Pharmaceutical Wholesalers Under Inspection
10 Feb
Risk-Based Audits

GDP Compliance Support for Pharmaceutical Wholesalers Under Inspection

CAPA Remediation Support After Regulatory Inspections
05 Feb
Pharmacovigilance Services

CAPA Remediation Support After Regulatory Inspections

Vendor Audit Programs for GMP and PV: What Regulators Expect to See
03 Feb
GVP Audits

Vendor Audit Programs for GMP and PV: What Regulators Expect to See

QPPV Services for MAHs: Defining Real Oversight in Outsourced PV Models
29 Jan
Pharma Audits Pharmacovigilance Services

QPPV Services for MAHs: Defining Real Oversight in Outsourced PV Models

Do You Need a Pharmacovigilance Audit? Key Signs for UK Pharma Companies
27 Jan
Pharma Audits

Do You Need a Pharmacovigilance Audit? Key Signs for UK Pharma Companies

Internal vs External Audits in GMP and Pharmacovigilance: What UK Regulators Expect
22 Jan
Pharma Audits

Internal vs External Audits in GMP and Pharmacovigilance: What UK Regulators Expect

Top GMP and Pharmacovigilance Audit Findings and How to Avoid Them
20 Jan
Pharma Audits

Top GMP and Pharmacovigilance Audit Findings and How to Avoid Them

MHRA Inspection Readiness: A Detailed January Checklist for UK Pharma Companies
15 Jan
Pharma Audits

MHRA Inspection Readiness: A Detailed January Checklist for UK Pharma Companies

GMP, GDP and GVP Audits: What Pharma Companies Should Plan at the Start of the Year
13 Jan
GVP Audits Pharma Audits

GMP, GDP and GVP Audits: What Pharma Companies Should Plan at the Start of the Year

Top 5 Regulatory Changes Impacting Pharma in 2026 (And How to Prepare)
08 Jan
Pharma Audits

Top 5 Regulatory Changes Impacting Pharma in 2026 (And How to Prepare)

The Cost of Non-Compliance: Why Investing in Quality Systems Pays Off in 2026
06 Jan
Pharmacovigilance Services

The Cost of Non-Compliance: Why Investing in Quality Systems Pays Off in 2026

Post-Market Surveillance Evolution: What Changed in PV Regulations for 2026
01 Jan
Pharmacovigilance Services

Post-Market Surveillance Evolution: What Changed in PV Regulations for 2026

AI-Driven GMP Audits: Transforming Pharma Compliance in 2026
30 Dec
GVP Audits

AI-Driven GMP Audits: Transforming Pharma Compliance in 2026

Risk-Based Auditing: How to Spot Problems Before They Become Crises
25 Dec
Risk-Based Audits

Risk-Based Auditing: How to Spot Problems Before They Become Crises

GxP Inspection Trends for 2026: What Health Authorities Are Targeting Now
23 Dec
GVP Audits

GxP Inspection Trends for 2026: What Health Authorities Are Targeting Now

5 Critical Mistakes Companies Make During PV Inspections (And How to Avoid Them in 2026)
18 Dec
Pharmacovigilance Services

5 Critical Mistakes Companies Make During PV Inspections (And How to Avoid Them in 2026)

Why Your Pharmacovigilance System Master File Could Fail Your Next Inspection
16 Dec
Pharmacovigilance Services

Why Your Pharmacovigilance System Master File Could Fail Your Next Inspection

The Hidden Costs of Poor ICSR Case Processing: Why Quality Matters More Than Speed
11 Dec
Pharmacovigilance Services

The Hidden Costs of Poor ICSR Case Processing: Why Quality Matters More Than Speed

Real World Evidence RWE in Regulatory Submissions: FDA and EMA Acceptance Criteria
09 Dec
Pharmacovigilance Services

Real World Evidence RWE in Regulatory Submissions: FDA and EMA Acceptance Criteria

How to Prepare for an MHRA Inspection: Expert Tips from Quality and Vigilance
04 Dec
Pharma Audits

How to Prepare for an MHRA Inspection: Expert Tips from Quality and Vigilance

Let’s build a GxP-compliant future together.

Have a project in mind?

Partner with us to elevate your quality systems, ensure compliance, and drive meaningful business transformation.

Contact Us Now

Built with passion and purpose. Helping you grow smarter, not harder.

QUICK LINKS

CONTACT US

+44 7474964491
[email protected]

Newsletter Signup

Subscribe to our newsletter for the latest insights

Copyright © 2026 Quality Vigilance Ltd | All Rights Reserved || Powered by Prabisha Consulting

Newsletter Signup

Subscribe to our newsletter for the latest insights